PV3B.F EYEPOINT PHARMAC. DL-01

Healthcare Biotechnology Frankfurt Exchange
0.3060 EUR
Close of Nov 12, 2026
0.2900 15.32
Market cap
EUR 26.4M
P/E
-
P/B
0.20x
ROE
-215.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is PV3B.F undervalued?

Graham number

The Graham number of EYEPOINT PHARMAC. DL-01 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

EYEPOINT PHARMAC. DL-01 fundamental analysis

No fundamental analysis for EYEPOINT PHARMAC. DL-01 yet.

EYEPOINT PHARMAC. DL-01 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About EYEPOINT PHARMAC. DL-01

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase…

Full company profile